Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARNA 1.43 -0.05 (-3.04%)
price chart
Price Target Update On Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
A number of investment brokers have recently updated their price targets on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Analyst Review Alert: Arena Pharmaceuticals, Inc. (ARNA)
Wall Street analysts have a much less favorable assessment of Arena Pharmaceuticals, Inc. (ARNA), with a mean rating of 2.7.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT & Analyst Recommendation Review  Uptick Analyst
Arena Pharmaceuticals Inc. (ARNA) Jumps 9.66% on February 04
Arena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 9.66% to $1.59, representing a gain of $0.14 per share.
Biotech Beach: Needham Provides Updates on Gilead Sciences, Inc. (GILD), Arena ...
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
Arena Pharmaceuticals, Inc. (ARNA) Earns Hold Rating from Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.
Trending Stocks: Synta Pharmaceuticals Corp. (SNTA), Arena Pharmaceuticals ...
The company's RSI reading has hit 27.33. The stock edged lower by -3.11% to close previous trading session at USD 0.190.
Analyst's Roundup: Arena Pharmaceuticals, Inc.
The shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) currently has mean rating of 2.71 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 5 recommended as “HOLD”.
How Analysts Feel About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?  WallStreet.org
Shining on Major News: Yahoo! Inc. (NASDAQ:YHOO), Adaptimmune Therapeutics ...  Stock Transcript
Zacks Investment Research Upgrades Arena Pharmaceuticals, Inc. (ARNA) to "Buy"
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Market Beat.
Short Interest in Arena Pharmaceuticals, Inc. (ARNA) Decreases By 22.6%  Corvus Business Newswire
Arena Pharmaceuticals, Inc. (ARNA) Upgraded to Buy at Zacks Investment Research
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, AnalystRatings.
Technical Analysis: Arena Pharmaceuticals, Inc.  CWRU Observer
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Lowered by Zacks Investment ...  Corvus Business Newswire
Zacks Investment Research Lowers Arena Pharmaceuticals, Inc. (ARNA) to Hold
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, MarketBeat.
Arena Pharmaceuticals, Inc. Analyst Rating Update  Analyst Rating Reports
Worth Watching Stocks: Arena Pharmaceuticals, Inc.  CWRU Observer